Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

A science-based weight loss protocol designed to help men lose fat, preserve muscle, and improve metabolic health ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

The Central Bank of Cyprus (CBC) has announced the issue of a €5 silver collector coin titled “Rigaina’s castles”, marking ...

First-ever randomized, placebo-controlled Phase 1 trial - published in The Lancet Microbe - supports SNIPR001’s safety, tolerability, and restriction to the gastrointestinal tract in healthy ...

The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients wi ...

Enrollment has been completed for a phase 2a randomized clinical trial evaluating the investigational microbiome therapeutic EBX-102-02 in patients undergoing allogeneic hematopoietic stem cell ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg ...

China’s innovation story has shifted from consumer internet platforms to industrial and technology infrastructure. Read more here.

The ratio of palladium to copper in an electrocatalyst governs syngas composition from CO2, shaping downstream carbon ...

POTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a ...

The larvae of the black soldier fly (Hermetia illucens) are considered a promising source of sustainable protein, as they contain high-quality protein comparable to soy protein. They can produce this ...